Myriad Genetics
MYGN announced today that Myriad RBM, a wholly owned subsidiary of
Myriad Genetics, has entered into a research collaboration with Sanofi, a
global and diversified healthcare leader, and Population Health Research
Institute (PHRI) at Hamilton Health Sciences and McMaster University. Through
this collaboration, Myriad RBM will perform protein biomarker research for the
Outcome Reduction with Initial Glargine Intervention (ORIGIN) study, the
world's longest and largest randomized clinical trial in pre- and early
diabetes. The relationship between the biomarker results and clinical outcomes
will be analyzed by investigators at PHRI.
As part of the agreement, Myriad RBM will analyze over 8,000 serum samples
collected in the ORIGIN study using its DiscoveryMAP^® 250+ quantitative
immunoassay panel. Sanofi conceived of the application of Myriad RBM's
technology to ORIGIN with a goal of identifying biomarker profiles that may
optimize treatment and improve patient care.
Funded by Sanofi and directed and managed by PHRI, ORIGIN is a unique,
six-year landmark cardiovascular (CV) outcomes trial, that evaluated Lantus®
(insulin glargine) versus standard care in over 12,500 individuals at high CV
risk with pre-diabetes or early type 2 diabetes mellitus. Spanning 40
countries worldwide, it was the world's longest and largest randomized
clinical trial of its type in this population.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in